Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822332 | 0.92 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL21311162 | 0.80 | ENPP1 (0.57) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.80 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL67131 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL26981114 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL1532103 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL2638945 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5015473 | 0.78 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL14037129 | 0.78 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL1635576 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896461-B2 | Polysilylated organosilane compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-9896461-B2 | Polysilylated organosilane compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20150218192-A1 | Polysilylated Organosilane Compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-08-06 | — | — | US | disclosed |
| US-20150218192-A1 | Polysilylated Organosilane Compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-08-06 | — | — | US | disclosed |
| WO-2014006221-A1 | POLYSILYLATED ORGANOSILANE COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2014-01-09 | — | — | WO | disclosed |
| US-8518885-B2 | Heterocyclic peptide ketoamides | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518885-B2 | Heterocyclic peptide ketoamides | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218192-A1 | Polysilylated Organosilane Compounds | ALG8, UGT1A9, SI | ADORA2A 4370/4885ADORA1 4554/4885ADORA2B 4617/4885 |
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | CAPNS1, CAPN1, CAPN2 | ADORA2A 4382/4885ADORA1 3735/4885ADORA2B 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.